JP2020515235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515235A5 JP2020515235A5 JP2019536937A JP2019536937A JP2020515235A5 JP 2020515235 A5 JP2020515235 A5 JP 2020515235A5 JP 2019536937 A JP2019536937 A JP 2019536937A JP 2019536937 A JP2019536937 A JP 2019536937A JP 2020515235 A5 JP2020515235 A5 JP 2020515235A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- domain antibody
- single domain
- isolated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 35
- 239000011230 binding agent Substances 0.000 claims 18
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 10
- 102000048362 human PDCD1 Human genes 0.000 claims 10
- 230000003993 interaction Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 5
- 229940127121 immunoconjugate Drugs 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 238000002619 cancer immunotherapy Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 101150117115 V gene Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000048119 human PDCD1LG2 Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022158582A JP7525567B2 (ja) | 2017-01-06 | 2022-09-30 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1700207.2A GB201700207D0 (en) | 2017-01-06 | 2017-01-06 | Single domain antibodies to prgrammed cell death (PD-1) |
| GBGB1700208.0A GB201700208D0 (en) | 2017-01-06 | 2017-01-06 | Single domain antibodies to programmed cell death (PD-1) |
| GB1700208.0 | 2017-01-06 | ||
| GB1700210.6 | 2017-01-06 | ||
| GB1700207.2 | 2017-01-06 | ||
| GBGB1700210.6A GB201700210D0 (en) | 2017-01-06 | 2017-01-06 | Single domain antibodies to programmed cell death (PD-1) |
| PCT/GB2018/050035 WO2018127709A1 (en) | 2017-01-06 | 2018-01-08 | Single domain antibodies to programmed cell death (pd-1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158582A Division JP7525567B2 (ja) | 2017-01-06 | 2022-09-30 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515235A JP2020515235A (ja) | 2020-05-28 |
| JP2020515235A5 true JP2020515235A5 (enExample) | 2021-02-18 |
| JP7183163B2 JP7183163B2 (ja) | 2022-12-05 |
Family
ID=60953895
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536936A Active JP7267921B2 (ja) | 2017-01-06 | 2018-01-08 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| JP2019536937A Active JP7183163B2 (ja) | 2017-01-06 | 2018-01-08 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| JP2022158582A Active JP7525567B2 (ja) | 2017-01-06 | 2022-09-30 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| JP2022177574A Pending JP2023010753A (ja) | 2017-01-06 | 2022-11-04 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536936A Active JP7267921B2 (ja) | 2017-01-06 | 2018-01-08 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158582A Active JP7525567B2 (ja) | 2017-01-06 | 2022-09-30 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| JP2022177574A Pending JP2023010753A (ja) | 2017-01-06 | 2022-11-04 | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US11591398B2 (enExample) |
| EP (3) | EP3565842A1 (enExample) |
| JP (4) | JP7267921B2 (enExample) |
| CN (2) | CN110167966B (enExample) |
| WO (3) | WO2018127711A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| JP7312168B2 (ja) | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| EP3864049A1 (en) * | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| EP3882269A4 (en) | 2018-11-16 | 2022-10-12 | Nanjing GenScript Biotech Co., Ltd. | HUMANIZED MONOCLONAL ANTI-HUMAN PD-L1 ANTIBODY, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| WO2020198075A2 (en) * | 2019-03-22 | 2020-10-01 | Reflexion Pharmaceuticals, Inc. | Multivalent d-peptidic compounds for target proteins |
| CN110003336B (zh) * | 2019-04-12 | 2023-05-12 | 深圳普瑞金生物药业股份有限公司 | Pd-1单域抗体、核苷酸序列及试剂盒 |
| WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| EP3733708A1 (en) * | 2019-05-02 | 2020-11-04 | Randox Laboratories Ltd | Immune checkpoint molecule inhibitor |
| KR20220008839A (ko) | 2019-05-15 | 2022-01-21 | 크레센도 바이오로직스 리미티드 | 결합 분자 |
| CN114728179A (zh) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | 利用pd-1激动剂的靶向免疫耐受 |
| CN112409483B (zh) * | 2019-08-22 | 2024-08-27 | 浙江道尔生物科技有限公司 | 抗pd-l1纳米抗体 |
| WO2021057836A1 (en) * | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN110950956B (zh) * | 2019-12-12 | 2022-03-08 | 源道隆（苏州）医学科技有限公司 | 可结合pd1的多肽及其应用 |
| JP7512413B2 (ja) * | 2020-03-31 | 2024-07-08 | ビオテウス・インコーポレイテッド | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 |
| GB202007452D0 (en) * | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| PH12022553181A1 (en) | 2020-05-26 | 2024-03-04 | Boehringer Ingelheim Int | Anti-pd-1 antibodies |
| CN114316022A (zh) * | 2020-09-30 | 2022-04-12 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| CN118240082A (zh) * | 2020-12-28 | 2024-06-25 | 浙江纳米抗体技术中心有限公司 | Pd-1结合分子及其应用 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| PE20241732A1 (es) * | 2021-03-31 | 2024-08-19 | Merus Nv | Dominios de union a pd-1 novedosos |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| GB202205589D0 (en) * | 2022-04-14 | 2022-06-01 | Crescendo Biologics Ltd | Mesothelin binders |
| CN117866905B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基于纳米抗体基因修饰的干细胞及其制备方法和产品 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113120D0 (en) * | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| ES2559002T3 (es) | 2001-10-23 | 2016-02-10 | Psma Development Company, L.L.C. | Anticuerpos contra PSMA |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| AU2004253738A1 (en) * | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| WO2006089230A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2718705A1 (en) | 2008-03-17 | 2009-09-24 | Allergan, Inc. | S1p3 receptor inhibitors for treating inflammation |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| US20130202623A1 (en) * | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2014501515A (ja) | 2010-12-01 | 2014-01-23 | グラクソ グループ リミテッド | 改良された抗血清アルブミン結合単一可変ドメイン |
| MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| CN103087171B (zh) | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| CN103333249A (zh) | 2013-06-14 | 2013-10-02 | 广州康合生物科技有限公司 | 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用 |
| EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| US20150201768A1 (en) | 2014-01-22 | 2015-07-23 | Thomas J. Bower | Dining napkin with special perforation feature |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| KR20150089702A (ko) * | 2014-01-28 | 2015-08-05 | 제일모직주식회사 | 신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터 |
| KR20160106762A (ko) | 2014-01-28 | 2016-09-12 | 브리스톨-마이어스 스큅 컴퍼니 | 혈액 악성종양을 치료하기 위한 항-lag-3 항체 |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MA39378B2 (fr) | 2014-04-25 | 2021-02-26 | Pf Medicament | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9982053B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| US11547099B2 (en) | 2014-10-22 | 2023-01-10 | Crescendo Biologies Limited | Transgenic mice |
| WO2016073760A1 (en) * | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Methods for stratifying non-responders to therapies that block pd1/pdl1 axis |
| CA3175979A1 (en) * | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| AU2016262845B2 (en) | 2015-05-18 | 2020-07-23 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| HUE055207T2 (hu) | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| AU2016334623A1 (en) | 2015-10-07 | 2018-02-15 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory TNF receptor |
| SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| MX2018008308A (es) | 2016-01-11 | 2019-05-15 | Inhibrx Inc | Proteinas de fusion de union a 41bb multivalentes y multiespecificas. |
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| CA3024723A1 (en) | 2016-05-20 | 2017-11-23 | Robert B. Dubridge | Single domain serum albumin binding protein |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| CA3052291A1 (en) | 2017-02-09 | 2018-08-16 | Memorial Sloan Kettering Cancer Center | Anti-kir3dl1 antibodies |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| EP3425763B1 (en) | 2017-07-03 | 2020-11-18 | France Brevets | Coupling interface and method of operation |
| TW202542197A (zh) | 2017-07-06 | 2025-11-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| JP7312168B2 (ja) | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| GB201818460D0 (en) | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| KR20220008839A (ko) | 2019-05-15 | 2022-01-21 | 크레센도 바이오로직스 리미티드 | 결합 분자 |
-
2018
- 2018-01-08 EP EP18700245.6A patent/EP3565842A1/en not_active Withdrawn
- 2018-01-08 JP JP2019536936A patent/JP7267921B2/ja active Active
- 2018-01-08 WO PCT/GB2018/050037 patent/WO2018127711A1/en not_active Ceased
- 2018-01-08 EP EP18700243.1A patent/EP3565840A1/en not_active Withdrawn
- 2018-01-08 US US16/475,597 patent/US11591398B2/en active Active
- 2018-01-08 US US16/475,590 patent/US11814429B2/en active Active
- 2018-01-08 CN CN201880006096.9A patent/CN110167966B/zh not_active Expired - Fee Related
- 2018-01-08 EP EP18700244.9A patent/EP3565841A1/en not_active Withdrawn
- 2018-01-08 US US16/475,599 patent/US11312771B2/en active Active
- 2018-01-08 CN CN201880005715.2A patent/CN110121510B/zh active Active
- 2018-01-08 WO PCT/GB2018/050036 patent/WO2018127710A1/en not_active Ceased
- 2018-01-08 JP JP2019536937A patent/JP7183163B2/ja active Active
- 2018-01-08 WO PCT/GB2018/050035 patent/WO2018127709A1/en not_active Ceased
-
2022
- 2022-03-29 US US17/706,839 patent/US20220306744A1/en not_active Abandoned
- 2022-09-30 JP JP2022158582A patent/JP7525567B2/ja active Active
- 2022-11-04 JP JP2022177574A patent/JP2023010753A/ja active Pending
-
2023
- 2023-02-10 US US18/167,318 patent/US20230357405A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515235A5 (enExample) | ||
| JP2020503870A5 (enExample) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| CN107973854B (zh) | Pdl1单克隆抗体及其应用 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2021502104A5 (enExample) | ||
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| Yu et al. | Single domain antibody: Development and application in biotechnology and biopharma | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| JP2019527553A5 (enExample) | ||
| JP7713995B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| JP2008520186A5 (enExample) | ||
| US9683032B2 (en) | Anti-S100A4 antibody molecules and their uses | |
| WO2022135536A1 (zh) | Cd3人源化抗体及其应用 | |
| JP2012523848A5 (enExample) | ||
| JP7624497B2 (ja) | ヒトｐｄ－ｌ２抗体およびその使用方法 | |
| TW201942130A (zh) | 結合至ssea4的單株抗體及其用途 | |
| EP4458854A1 (en) | Gprc5d antibody and application thereof | |
| US20240182563A1 (en) | Anti-cntn4 antibody and use thereof | |
| US20250136687A1 (en) | Anti-human cd3 antibody and use thereof | |
| JP2014515600A5 (enExample) | ||
| JP2025507938A (ja) | 抗ｐｄ－ｌ２抗体 | |
| AU2021446021A1 (en) | Anti-bcam antibody or antigen-binding fragment thereof | |
| CN119698434A (zh) | 抗gprc5d纳米抗体及其应用 | |
| JPWO2019158942A5 (enExample) |